EVANSTON, Ill., Nov. 7 /PRNewswire/ -- Northfield Laboratories Inc.
(Nasdaq: NFLD), reported that it attended two scientific conferences, one
investor forum and hosted its annual business update in October to highly
responsive investor and industry audiences.
Feedback from its annual business update, webcast on October 12, 2000,
was substantial and overwhelmingly positive. Richard DeWoskin, chairman and
chief executive officer, said the company's objective in webcasting the
recent presentation was to allow shareholders and other interested parties
to simultaneously receive an update on the company as well as direct access
to management's remarks. The online format of the presentation was a
resounding success, and increased the average annual meeting attendance
more than ten-fold. As a result, management is considering holding an online
mid-year update in the spring.
In late October, Northfield's President, Steven A. Gould, M.D., spoke to
another group of investors at the Midwest BioMarketplace conference, presented
by the Chicago Biotech Network. This forum, attended by leading biotechnology
analysts, gave the company access to a new group of potential investors and
further increased awareness of the company's superior product and impressive
clinical data.
On October 24 and 28, Gould presented a clinical update to the scientific
community at the American College of Surgeons Annual Clinical Congress and the
Illinois Society of Anesthesiologists Fall Meeting, respectively. Physician
response was highly favorable and enthusiastic about the important role
PolyHeme may play in the treatment of urgent blood loss.
The common thread throughout all of the presentations -- investor and
scientific -- was to update participants on Northfield's clinical success in
the treatment of urgent blood loss, the company's primary focus. To the
scientific audience, Northfield stressed the remarkable survival benefit it
has achieved using its oxygen-carrying blood substitute, PolyHeme(TM), in
massive blood-loss situations. Investors were brought up to date on the
regulatory process and the important progress the company has made toward a
filing of PolyHeme, noting that it believes it is adequately and appropriately
addressing all of the FDA issues.
Upcoming Presentations
Northfield will be making presentations at one scientific and one business
conference in early November: the NATO Civil-Military Blood Conference, and
the Prudential-Vector Securities Health Care Conference, both taking place
November 8 and 9.
Northfield Laboratories was founded in 1985. The company is headquartered
in Evanston, Illinois, and its stock is traded on the Nasdaq National Market
System under the symbol NFLD.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks include, among others: competition from other blood
substitute products; the company's ability to obtain regulatory approval to
market PolyHeme commercially; the company's ability to successfully market and
sell PolyHeme; the company's ability to manufacture PolyHeme in sufficient
quantities; the company's ability to obtain an adequate supply of raw
materials; the company's ability to maintain intellectual property protection
for its proprietary product and to defend its existing intellectual property
rights from challenges by third parties; the availability of capital to
finance planned growth; and the extent to which the hospitals and physicians
using PolyHeme are able to obtain third-party reimbursement, as described in
the company's filing with the Securities and Exchange Commission.
For more information on Northfield Laboratories Inc. via facsimile at no
cost, simply dial 1-800-PRO-INFO and enter the company code NFLD.
Visit the Northfield website at: http://www.northfieldlabs.com
SOURCE Northfield Laboratories
 back to top
Related links:
http://www.northfieldlabs.com
CONTACT:
Richard DeWoskin, Chief Executive Officer,
847-864-3500, or Investor Relations, 847-864-0502, both of
Northfield Laboratories; or General Information, Leslie Hunziker,
312-640-6760, of The Financial Relations Board
|
